Affordable Access

deepdyve-link
Publisher Website

Quality-of-life assessment in French patients with metastatic melanoma in real life.

Authors
  • Kandel, Marguerite1, 2
  • Dalle, Stéphane3
  • Bardet, Aurélie1, 2
  • Allayous, Clara4
  • Mortier, Laurent5
  • Dutriaux, Caroline6
  • Guillot, Bernard7
  • Leccia, Marie-Thérèse8
  • Dalac, Sophie9
  • Legoupil, Delphine10
  • Saiag, Philippe11
  • Montaudie, Henri12
  • Arnault, Jean-Philippe13
  • Brunet-Possenti, Florence14
  • Grob, Jean-Jacques15
  • DeQuatrebarbes, Julie16
  • Beylot-Barry, Marie17
  • Lesimple, Thierry18
  • Aubin, François19
  • Maubec, Eve20
  • And 7 more
  • 1 Biostatistics and Epidemiology Service, Gustave Roussy Institute, Villejuif, France. , (France)
  • 2 Center for Research in Epidemiology and Population Health, University of Paris-Saclay, University of Paris-Sud, and Versailles-Saint-Quentin-en-Yvelines University, French Institute of Health and Medical Research (INSERM), Villejuif, France. , (France)
  • 3 Dermatology Unit, Cancer Research Center of Lyon, Lyon University Hospital, Claude Bernard University, Lyon, France. , (France)
  • 4 Dermatology Unit, Clinical Investigation Center, Public Hospital of Paris (AP-HP), INSERM Unit 976, Paris Diderot University-Saint-Louis Hospital, Paris, France. , (France)
  • 5 ONCO-THAI, INSERM Unit 1189, Lille University, Lille Hospital, Lille, France. , (France)
  • 6 Dermatology Unit, Bordeaux Saint-Andre Hospital, Bordeaux, France. , (France)
  • 7 Dermatology Unit, Montpellier Hospital, Montpellier, France. , (France)
  • 8 Dermatology Unit, Grenoble Hospital, Grenoble, France. , (France)
  • 9 Dermatology Unit, Dijon Hospital, Dijon, France. , (France)
  • 10 Dermatology Unit, Brest Hospital, Brest, France. , (France)
  • 11 Dermatology Unit, Ambroise Pare Hospital, AP-HP, Boulogne-Billancourt, France. , (France)
  • 12 Dermatology Unit, Nice Hospital, Nice, France. , (France)
  • 13 Dermatology Unit, Amiens Hospital, Amiens, France. , (France)
  • 14 Dermatology Unit, Bichat Hospital, AP-HP, Paris, France. , (France)
  • 15 Dermatology Unit, La Timone Hospital, Marseilles, France. , (France)
  • 16 Dermatology Unit, Annecy Hospital, Annecy, France. , (France)
  • 17 Dermatology Unit, Bordeaux Haut-L'eveque Hospital, Bordeaux, France. , (France)
  • 18 Rennes Eugene Marquis, Cancer Center, Rennes, France. , (France)
  • 19 Dermatology Unit, Besancon Hospital, Besancon, France. , (France)
  • 20 Dermatology Unit, Avicennes Hospital, AP-HP, Paris, France. , (France)
  • 21 Dermatology Unit, Nancy Hospital, Nancy, France. , (France)
  • 22 Dermatology Unit, Nimes Hospital, Nimes, France. , (France)
  • 23 Dermatology Unit, Rennes Hospital, Rennes, France. , (France)
  • 24 Dermatology Unit, Nantes Hospital, Nantes, France. , (France)
  • 25 Research Group in Law and Health Economics, University Paris-Sud, Paris, France. , (France)
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 01, 2020
Volume
126
Issue
3
Pages
611–618
Identifiers
DOI: 10.1002/cncr.32554
PMID: 31639198
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of -0.027 (95% CI, -0.03, -0.02) in the utility score, -1.82 (95% CI, -1.88, -1.76) in the FACT-General score, and -2.98 (95% CI, -3.05, -2.91) in the FACT-Melanoma score compared with first-line treatment. In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed. © 2019 American Cancer Society.

Report this publication

Statistics

Seen <100 times